Saxenda^® (liraglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

• Adult patients with an initial body mass index (BMI) of:¹
  • 30 kg/m² or greater (obesity), or
  • 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.
• Pediatric patients aged 12 to less than 18 years with:¹
  • an inadequate response to reduced calorie diet and increased physical activity alone, and
  • a body weight above 60 kg (132 lbs), and
  • an initial body mass index (BMI) corresponding to ≥ 30 kg/m² for adults (obesity) by international cut-offs

Limitations of use:

• Clinical efficacy and safety data from patients with BMI 27 to 29.9 kg/m² in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) are limited (N = 149).
• The safety and effectiveness of Saxenda^® in pediatric patients with type 2 diabetes have not been established.

Please consult the Product Monographor click herefor more information on:

• Contraindications in patients with personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), pregnant and breastfeeding women
• The most serious warning and precaution regarding the risk of thyroid C-cell tumours
• Other relevant warnings and precautions regarding combination use with other weight loss products; administration considerations; risk of breast neoplasms; risk of increased heart rate and PR interval prolongation; use in patients with recent myocardial infarction, unstable angina, and congestive heart failure; driving and operating machinery; severe hypoglycemia risk in patients with type 2 diabetes; gastrointestinal disease; use in patients with hepatic or renal insufficiency; acute pancreatitis and gallbladder disease; hypersensitivity reactions; suicidal behaviour and ideation
• Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.